All posts by medical

Study provides genetic explanation behind the sex bias observed in certain diseases – News-Medical.Net

Some diseases exhibit a clear sex bias, occurring more often, hitting harder or eliciting different symptoms in men or women.

For instance, the autoimmune conditions lupus and Sjgren's syndrome affect nine times more women than men, while schizophrenia affects more men and tends to cause more severe symptoms in men than in women.

Likewise, early reports suggest that despite similar rates of infection, men are dying from COVID-19 more often than women, as happened during previous outbreaks of the related diseases SARS and MERS.

For decades, scientists have tried to pinpoint why some diseases have an unexpected sex bias. Behavior can play a role, but that explains only a piece of the puzzle. Hormones are commonly invoked, but how exactly they contribute to the disparity is unclear. As for genes, few, if any, answers have been found on the X and Y sex chromosomes for most diseases.

Now, work led by researchers in the Blavatnik Institute at Harvard Medical School and at the Broad Institute of MIT and Harvard provides a clear genetic explanation behind the sex bias observed in some of these diseases.

The team's findings, reported May 11 in Nature, suggest that greater abundance of an immune-related protein in men protects against lupus and Sjgren's but heightens vulnerability to schizophrenia.

The protein, called complement component 4 (C4) and produced by the C4 gene, tags cellular debris for prompt removal by immune cells.

The team's key findings:

"Sex acts as a lens that magnifies the effects of genetic variation," said the study's first author, Nolan Kamitaki, research associate in genetics in the lab of Steven McCarroll at HMS and the Broad.

We all know about illnesses that either women or men get a lot more, but we've had no idea why. This work is exciting because it gives us one of our first handles on the biology."

Steven McCarroll, Dorothy and Milton Flier Professor of Biomedical Science and Genetics, HMS

McCarroll is the director of genomic neurobiology at the Stanley Center for Psychiatric Research at the Broad. McCarroll is also the co-senior author of the study with Timothy Vyse of King's College London.

Although C4 variation appears to contribute powerfully to disease risk, it is only one among many genetic and environmental factors that influence disease development.

The study's results are informing the ongoing development of drugs that modulate the complement system, the authors said.

"For example, researchers will need to make sure that drugs that tone down the complement system do not unintentionally increase risk for autoimmune disease," said McCarroll. "Scientists will also need to consider the possibility that such drugs may be differentially helpful in male and female patients."

On a broader level, the work offers a more solid foundation for understanding sex variation in disease than has been available before.

"It's helpful to be able to think about sex-biased disease biology in terms of specific molecules, beyond vague references to 'hormones,'" McCarroll said. "We now realize that the complement system shapes vulnerability for a wide variety of illnesses."

In 2016, researchers led by Aswin Sekar, a former McCarroll lab member who is a co-author of the new study, made international headlines when they revealed that specific C4 gene variants underlie the largest common genetic risk factor for developing schizophrenia.

The new work suggests that C4 genes confer both an advantage and disadvantage to carriers, much as the gene variant that causes sickle cell disease also protects people against malaria.

"C4 gene variants come with this yin and yang of heightened and reduced vulnerability in different organ systems," said McCarroll.

The findings, when combined with insights from earlier work, offer insights into what may be happening at the molecular level.

When cells are injured, whether from a sunburn or infection, they leak their contents into the surrounding tissue. Cells from the adaptive immune system, which specialize in recognizing unfamiliar molecules around distressed cells, spot debris from the cell nuclei.

If these immune cells mistake the flotsam for an invading pathogen, they may instigate an attack against material that isn't foreign at all--the essence of autoimmunity.

Researchers believe that complement proteins help tag these leaked molecules as trash so they're quickly removed by other cells, before the adaptive immune system pays too much attention to them.

In people with lower levels of complement proteins, however, the uncollected debris lingers longer, and adaptive immune cells may become confused into acting as if the debris is itself the cause of problem.

As part of the new study, Kamitaki and colleagues measured complement protein levels in the cerebrospinal fluid of 589 people and blood plasma of 1,844 people. They found that samples from women aged 20 through 50 had significantly fewer complement proteins--including not only C4 but also C3, which activates C4--than samples from men of the same age.

That's the same age range in which lupus, Sjgren's and schizophrenia vulnerabilities differ by sex, Kamitaki said.

The results align with previous observations by other groups that severe early-onset lupus is sometimes associated with a complete lack of complement proteins, that lupus flare-ups can be linked to drops in complement protein levels and that a common gene variant associated with lupus affects the C3 receptor.

"There were all these medical hints," said McCarroll. "Human genetics helps put those hints together."

The bulk of the findings arose from analyses of whole genomes from 1,265 people along with single nucleotide polymorphism (SNP) data from 6,700 people with lupus and 11,500 controls.

C4 genes and proteins come in two types, C4A and C4B. The researchers found that having more copies of the C4A gene and higher levels of C4A proteins was associated with greater protection against lupus and Sjgren's, while C4B genes had a significant but more modest effect. On the other hand, C4A was linked with increased risk of schizophrenia, while C4B had no effect on that illness.

In men, common combinations of C4A and C4B produced a 14-fold range of risk for lupus and 31-fold range of risk for Sjgren's, compared to only 6-fold and 15-fold ranges in women, respectively.

The researchers didn't expect the genes' effects to be so strong.

Large genetic effects tend to come from rare variants, while common gene variants generally have small effects. The C4 gene variants are common, yet they are very impactful in lupus and Sjgren's."

Steven McCarroll, Dorothy and Milton Flier Professor of Biomedical Science and Genetics, HMS

Still, complement genes don't tell the full story of lupus, Sjgren's or schizophrenia risk, none of which are caused entirely by genetics.

"The complement system contributes to the sex bias, but it's only one of probably many genetic and environmental contributors," said Kamitaki.

Complement genes and another family of immune-related genes, called human leukocyte antigen or HLA genes, are interspersed throughout the same complex stretch of the human genome. HLA variants have been shown to raise risk of developing other autoimmune diseases, including type 1 diabetes, celiac disease and rheumatoid arthritis, and researchers had long believed that something similar was happening with lupus and Sjgren's.

The culprit, however, remained stubbornly hard to pin down, because specific variants in HLA genes and C4 genes always seemed to appear together in the same people.

Kamitaki and colleagues overcame this hurdle by analyzing DNA from a cohort of several thousand African American research participants. The participants' DNA contained many more recombinations between complement and HLA genes, allowing the researchers to finally tease apart the genes' contributions.

"It became quite clear which gene was responsible," said McCarroll. "That was a real gift to science from African American research participants. The question had been unsolved for decades."

The discovery provides further proof that the field of genetics would benefit from diversifying the populations it studies, McCarroll said.

"It will really help for genetics to expand more strongly beyond European ancestries and learn from genetic variation and ancestries all over the world," he said.

C4 variation could contribute to sex-based vulnerabilities in other diseases not yet analyzed, the authors said. It's not yet clear whether C4 pertains to the sex bias seen in COVID-19.

"We don't know the mechanism yet for why men seem to get sicker from COVID-19," said McCarroll. "Complement molecules are potentially important in any immune or inflammatory condition, and in COVID-19, it seems the immune response can be part of a downward spiral in some patients. But we don't know the key details yet."

It also remains to be seen how the differing effects of complement genes apply to people with intersex traits, also known as disorders or differences of sex development, who don't always fit textbook genetic or biological definitions of male and female.

"That is important to understand," said McCarroll.

Source:

Journal reference:

Kamitaki, N., et al. (2020) Complement genes contribute sex-biased vulnerability in diverse disorders. Nature. doi.org/10.1038/s41586-020-2277-x.

See original here:
Study provides genetic explanation behind the sex bias observed in certain diseases - News-Medical.Net

Seattle Genetics Announces the Approval of TUKYSA (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer…

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc., Inc. (Nasdaq:SGEN) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA (tucatinib) tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast cancer, who have previously received two or more anti-HER2 regimens in any setting, including trastuzumab, pertuzumab and trastuzumab-emtansine (TDM1).

The application for TUKYSA approval was reviewed by Swissmedic as part of Project Orbis, an initiative of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology drugs among participating international regulatory agencies in Canada, Australia and Singapore. On April 17, the FDA approved TUKYSA in the U.S. under the FDAs Real-Time Oncology Review (RTOR) pilot program, four months prior to its action date, and represented the first new drug approved under Project Orbis.

Were grateful to Swissmedic for their collaboration through FDAs Project Orbis in approving this important new medicine in Switzerland, said Jennifer Stephens, Vice President of Regulatory Affairs at Seattle Genetics. We're committed to bringing new targeted therapies to patients, and we are excited about this important first step toward making TUKYSA available to patients in Switzerland.

TUKYSA is an oral, small molecule tyrosine kinase inhibitor (TKI) of HER2, a protein that contributes to cancer cell growth.i,ii

The approval is based on results from the pivotal trial HER2CLIMB, a randomized (2:1), double-blind, placebo-controlled trial that enrolled 612 patients with HER2-positive unresectable locally advanced or metastatic breast cancer who had previously received, either separately or in combination, trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1). The study results were published in The New England Journal of Medicine in December 2019.

About HER2-Positive Breast Cancer

Patients with HER2-positive breast cancer have tumors with high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. In 2018, more than two million new cases of breast cancer were diagnosed worldwide, including 522,513 in Europe. iii Between 15 and 20 percent of breast cancer cases are HER2-positive.iv Historically, HER2-positive breast cancer tends to be more aggressive and more likely to recur than HER2-negative breast cancer.v,vi,vii Up to 50 percent of metastatic HER2-positive breast cancer patients develop brain metastases over time.viii,ix,x

About TUKYSA (tucatinib)

TUKYSA is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein. In vitro (in lab studies), TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In vivo (in living organisms), TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either medicine alone.xi In the U.S., TUKYSA is approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Important U.S. Safety Information

Warnings and Precautions

If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

Adverse Reactions

Serious adverse reactions occurred in 26% of patients who received TUKYSA. Serious adverse reactions in 2% of patients who received TUKYSA were diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). Fatal adverse reactions occurred in 2% of patients who received TUKYSA including sudden death, sepsis, dehydration, and cardiogenic shock.

Adverse reactions led to treatment discontinuation in 6% of patients who received TUKYSA; those occurring in 1% of patients were hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions led to dose reduction in 21% of patients who received TUKYSA; those occurring in 2% of patients were hepatotoxicity (8%) and diarrhea (6%).

The most common adverse reactions in patients who received TUKYSA (20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea, fatigue, hepatotoxicity, vomiting, stomatitis, decreased appetite, abdominal pain, headache, anemia, and rash.

Lab Abnormalities

In HER2CLIMB, Grade 3 laboratory abnormalities reported in 5% of patients who received TUKYSA were: decreased phosphate, increased ALT, decreased potassium, and increased AST. The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.

Drug Interactions

Use in Specific Populations

For more information, please see the full Prescribing Information for TUKYSA here.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSATM (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in Bothell, Washington, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of TUKYSA including its efficacy, safety and therapeutic uses including the potential use of TUKYSA in combination with trastuzumab and capecitabine for the treatment of patients with metastatic HER2-positive breast cancer, who have previously received two or more anti-HER2 regimens in any setting, including trastuzumab, pertuzumab and trastuzumab-emtansine (TDM1) and the potential to bring TUKYSA to patients in Switzerland. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include reimbursement processes, the extent of reimbursement, the possibility that adverse events or safety signals may occur, the possibility that the ultimate utilization and adoption of TUKYSA by prescribing physicians may be limited, including due to impacts related to the COVID-19 pandemic, the possibility of difficulties in supplying and commercializing a new therapeutic agent, and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

i TUKYSA [package insert]. Bothell, WA: Seattle Genetics, Inc.ii Anita Kulukian, Patrice Lee, Janelle Taylor, et al. Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor ModelsMol Cancer Ther 2020;19:976-987.iii Breast. Globocan 2018. World Health Organization. 2019. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf iv Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785): 177-82.v Loibli S, Gianni L. HER2-positive breast cancer. Lancet. 2017; 389(10087): 2415-29.vi Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785): 177-82.vii Breast Cancer HER2 Status. American Cancer Society website. http://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html. Accessed March 9, 2020.viii Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37:1081-1089.ix Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013;22:525-531.x Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972-2977.xi TUKYSA [package insert]. Bothell, WA: Seattle Genetics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005217/en/

Read more here:
Seattle Genetics Announces the Approval of TUKYSA (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer...

Discovery of How the Brain Links Memories Could Offer Route to Trauma Therapies – Technology Networks

A woman walking down the street hears a bang. Several moments later she discovers her boyfriend, who had been walking ahead of her, has been shot. A month later, the woman checks into the emergency room. The noises made by garbage trucks, she says, are causing panic attacks. Her brain had formed a deep, lasting connection between loud sounds and the devastating sight she witnessed.This story, relayed by clinical psychiatrist and co-author of a new study Mohsin Ahmed, MD, PhD, is a powerful example of the brain's powerful ability to remember and connect events separated in time. And now, in that new study in mice published in Neuron,scientists at Columbia's Zuckerman Institute have shed light on how the brain can form such enduring links.

The scientists uncovered a surprising mechanism by which the hippocampus, a brain region critical for memory, builds bridges across time: by firing off bursts of activity that seem random, but in fact make up a complex pattern that, over time, help the brain learn associations. By revealing the underlying circuitry behind associative learning, the findings lay the foundation for a better understanding of anxiety and trauma- and stressor-related disorders, such as panic and post-traumatic stress disorders, in which a seemingly neutral event can elicit a negative response.

"We know that the hippocampus is important in forms of learning that involve linking two events that happen even up to 10 to 30 seconds apart," said Attila Losonczy, MD, PhD, a principal investigator at Columbia's Mortimer B. Zuckerman Mind Brain Behavior Institute and the paper's co-senior author. "This ability is a key to survival, but the mechanisms behind it have proven elusive. With today's study in mice, we have mapped the complex calculations the brain undertakes in order to link distinct events that are separated in time."

The hippocampus a small, seahorse-shaped region buried deep in the brain is an important headquarters for learning and memory. Previous experiments in mice showed that disruption to the hippocampus leaves the animals with trouble learning to associate two events separated by tens of seconds.

"The prevailing view has been that cells in the hippocampus keep up a level of persistent activity to associate such events," said Dr. Ahmed, an assistant professor of clinical psychiatry at Columbia's Vagelos College of Physicians and Surgeons, and co-first author of today's study. "Turning these cells off would thus disrupt learning."

To test this traditional view, the researchers imaged parts of the hippocampus of mice as the animals were exposed to two different stimuli: a neutral sound followed by a small but unpleasant puff of air. A fifteen-second delay separated the two events. The scientists repeated this experiment across several trials. Over time, the mice learned to associate the tone with the soon-to-follow puff of air. Using advanced two-photon microscopy and functional calcium imaging, they recorded the activity of thousands of neurons, a type of brain cell, in the animals' hippocampus simultaneously over the course of each trial for many days.

"With this approach, we could mimic, albeit in a simpler way, the process our own brains undergo when we learn to connect two events," said Dr. Losonczy, who is also a professor of neuroscience at Columbia's Vagelos College of Physicians and Surgeons.

To make sense of the information they collected, the researchers teamed up with computational neuroscientists who develop powerful mathematical tools to analyze vast amounts of experimental data.

"We expected to see repetitive, continuous neural activity that persisted during the fifteen-second gap, an indication of the hippocampus at work linking the auditory tone and the air puff," said computational neuroscientist Stefano Fusi, PhD, a principal investigator at Columbia's Zuckerman Institute and the paper's co-senior author. "But when we began to analyze the data, we saw no such activity."

Instead, the neural activity recorded during the fifteen-second time gap was sparse. Only a small number of neurons fired, and they did so seemingly at random. This sporadic activity looked distinctly different from the continuous activity that the brain displays during other learning and memory tasks, like memorizing a phone number.

"The activity appears to come in fits and bursts at intermittent and random time periods throughout the task," said James Priestley, a doctoral candidate co-mentored by Drs. Losonczy and Fusi at Columbia's Zuckerman Institute and the paper's co-first author. "To understand activity, we had to shift the way we analyzed data and use tools designed to make sense of random processes."

Ultimately, the researchers discovered a pattern in the randomness: a style of mental computing that seems to be a remarkably efficient way that neurons store information. Instead of communicating with each other constantly, the neurons save energy perhaps by encoding information in the connections between cells, called synapses, rather than through the electrical activity of the cells.

"We were happy to see that the brain doesn't maintain ongoing activity over all these seconds because, metabolically, that's not the most efficient way to store information," said Dr. Fusi, who is also a professor of neuroscience at Columbia's Vagelos College of Physicians and Surgeons. "The brain seems to have a more efficient way to build this bridge, which we suspect may involve changing the strength of the synapses."

In addition to helping to map the circuitry involved in associative learning, these findings also provide a starting point to more deeply explore disorders involving dysfunctions in associative memory, such as panic and post-traumatic stress disorder.

"While our study does not explicitly model the clinical syndromes of either of these disorders, it can be immensely informative," said Dr. Ahmed, who is also a member of the Losonczy lab at Columbia's Zuckerman Institute. "For example, it can help us to model some aspects of what may be happening in the brain when patients experience a fearful association between two events that would, to someone else, not elicit fright or panic."ReferenceAhmed et al. (2020). Hippocampal Network Reorganization Underlies the Formation of a Temporal Association Memory. Neuron. DOI: https://doi.org/10.1016/j.neuron.2020.04.013

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See more here:
Discovery of How the Brain Links Memories Could Offer Route to Trauma Therapies - Technology Networks

Ironshore to Present Posters at the 2020 Neuroscience Education Institute Virtual Scientific Poster Session – Business Wire

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Ironshore Pharmaceuticals Inc. (Ironshore), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD), today announced it is presenting two posters featuring new analyses of its novel delayed-release and extended-release methylphenidate formulation. These analyses demonstrate that the uniphasic drug delivery system and site of absorption produce a gradual absorption and protracted elimination phase resulting in attenuated peak drug concentration levels across the dosing range and may lead to a dose-dependent duration of effect. The posters are available for download at the Virtual Scientific Poster Session of the Neuroscience Education Institute (NEI). This initiative was coordinated in response to the COVID-19 pandemic and is designed to fill the void in the presentation and dissemination of emerging science historically presented during live meetings. The posters will be accessible to NEIs 65,700 members and subscribers at http://nei.global/vsp.

The two poster presentations are:

Model-Based Approach to Establish Predicted Clinical Response of Delayed-Release and Extended-Release Methylphenidate (DR/ER-MPH) for ADHD TreatmentRoberto Gomeni, PhD, Marina Komolova, PhD; Bev Incledon, PhD; Stephen V. Faraone, PhDhttps://www.neiglobal.com/VSP/NEIVSPDetail/tabid/562/args/7/Default.aspx

Site-Specific Colonic Absorption for an Optimized Pharmacokinetic Profile of DR/ER-MPH for the Treatment of ADHDFeng Zhang, PhD; Norberto J. DeSousa, MA; F. Randy Sallee, MD, PhD; David Lickrish; Bev Incledon, PhDhttps://www.neiglobal.com/VSP/NEIVSPDetail/tabid/562/args/6/Default.aspx

The posters will enable NEIs stakeholders to learn more about JORNAY PM (methylphenidate HCl) extended-release capsules CII, which was approved in August 2018 by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in patients 6 years and older.

Ironshore is proud to participate in NEIs innovative new forum to present data that are relevant to psychiatrists, psychiatric nurse practitioners, and other mental health care professionals, said Dr. Randy Sallee, Ironshores Chief Medical Officer. We look forward to sharing new data related to the unique absorption profile of JORNAY PM facilitated by the DELEXIS delayed-release, extended-release, drug delivery technology as well as an evaluation of the medicines pharmacokinetic profile, after single 20mg and 100mg doses, in relation to that of other FDA-approved stimulant medications.

Dr. Bev Incledon, EVP, Research & Development for Ironshore Pharmaceuticals & Development, Inc. added, Head-to-head studies assessing safety and efficacy of Jornay PM and other stimulants have not been conducted and Jornay PM is not substitutable with other methylphenidate products on a milligram per milligram basis. In this analysis, a 100-mg dose of JORNAY PM produces a maximum serum methylphenidate concentration that is either equal to or lower than that of 54mg and 60mg of other methylphenidate products. While this may surprise some healthcare professionals, this result is directly attributable to the site of absorption for Jornay PM, the colon, which has vastly different absorption qualities relative to the stomach and upper intestine. Although the Cmax was proportionately lower than expected, the absorption window was significantly longer. Together, this resulted in 74% bioavailability relative to a Ritalin IR comparator.

JORNAY PM is the first and only stimulant medication that is dosed in the evening and has demonstrated improved ADHD symptom control in the early morning, throughout the day and during the evening time period in two pivotal Phase 3 trials.

WARNING: ABUSE AND DEPENDENCE

See full prescribing information for complete boxed warning.

See additional important safety information below.

JORNAY PM is the first product to leverage the novel DELEXIS delayed-release and extended-release drug delivery technology that contains two functional film coatings. The first layer delays the initial release of drug for up to 10 hours while the second layer helps to control the rate of release of the active pharmaceutical ingredient from the time the patient awakens the next morning, throughout the day and into the evening.

About ADHDADHD is among the most common childhood psychiatric conditions with behavioral symptoms fluctuating throughout the day. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors, or be overly active. Many home-based difficulties for children and adolescents with ADHD occur during the early morning routine (i.e., before the school day begins).

About JORNAY PMDeveloped by Ironshore Pharmaceuticals & Development, Inc., JORNAY PM is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people six years of age and older. JORNAY PM may help increase attention and decrease impulsiveness and hyperactivity in people six years of age and older with ADHD. It is not known if JORNAY PM is safe and effective in children under six years of age.

JORNAY PM is dosed once daily in the evening and should be initiated at 8:00 p.m. Timing of administration of JORNAY PM may be adjusted between 6:30 p.m. and 9:30 p.m. to optimize the tolerability and the efficacy the next morning and throughout the day. The recommended starting dose for patients 6 years and older is 20 mg once daily in the evening. Dosage may be titrated weekly in increments of 20 mg per day up to maximum daily dose of 100 mg. The mean optimized dose required to improve symptoms from the time the patient wakes up, throughout the day and into the evening in children 6-12 years old was 67 mg in Study 1 and 68.1 mg in Study 2. The relative bioavailability of JORNAY PM (given once a day) compared to the same daily dose of a methylphenidate immediate-release oral product (given 3 times a day) in adults is approximately 74%. JORNAY PM is primarily absorbed in the colon which may contribute to the reduced bioavailability of the drug. JORNAY PM is not interchangeable on a milligram-per-milligram basis with other methylphenidate formulations.

Please see additional dosing information in the full prescribing information for JORNAY PM at http://ironshorepharma.com/labeling.pdf.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCECNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

PREGNANCY AND LACTATION

Please visit http://ironshorepharma.com/labeling.pdf for additional important safety information and the Full Prescribing Information, including Boxed Warning, for JORNAY PM.

About Ironshore Pharmaceuticals Inc.Ironshore Pharmaceuticals Inc. commercializes innovative, patient-centric treatment options to improve the lives of patients and caregivers. Based in North Carolina, Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US. Ironshore Pharmaceuticals Inc. is a wholly owned subsidiary of Highland Therapeutics Inc. based in Toronto, Canada.

About Ironshore Pharmaceuticals & Development, Inc.Ironshore Pharmaceuticals & Development, Inc., based in Grand Cayman, develops novel therapeutics by leveraging its proprietary drug-delivery technology, DELEXIS. Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Highland Therapeutics Inc. based in Toronto, Canada.

Forward-Looking StatementsThis press release contains forward-looking information, which reflects Ironshores current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Ironshores control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Ironshore assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View original post here:
Ironshore to Present Posters at the 2020 Neuroscience Education Institute Virtual Scientific Poster Session - Business Wire

How not to fight with your teenage son – Sydney Morning Herald

But the news isnt all good. Many parents are frightened. Their sons, often in their late teens, belligerent and angry at the restrictions, chafing to get out and meet with mates in secret.

There are many stories of fights over schoolwork and sullen and withdrawn sons not coming out of their rooms. Where relationships weren't great in pre-coronavirus times, this is a real crisis.

But if these problems are worked through, this might be a time when a lot of what we value most comes to the fore, and our kids remember the year of the virus as a special time, a reset, a reclaiming of what family is supposed to feel like.

Ahead, the parenting methods proving successful in lockdown.

Teamwork. Parents who are doing well have managed to create a family vibe similar to that of a team. They are not militantly supervising online schoolwork, at least, not to the point of conflict, but allocating at most a couple of hours for it in the flow of other things that are both fruitful and enjoyable.

Loading

Get moving. Exercise and movement are natural needs of teenagers. In the past, many parents thought that energy in boys was naughtiness, but thankfully that has mostly changed. Morning exercise, followed by the completion of any mandatory school work first, are key to setting up a productive day ahead.

Routine. The other need boys have, according to neuroscience, is lots of structure. Successful families found that a routine made for a happy and balanced day. They differed on sleeping in or everyone waking on time, but all found their own sequence to the day.

Try new things. Many families are getting their kids to make meals in equal share with the adults. A mum on the page allocated one part of the meal to her three sons in rotation - one the protein, one the veggies, one the dessert. She is teaching them how to work from recipes, while staying nearby in a friendly supervisory way so it doesn't feel like they are being abandoned, and also to prevent disasters. Her boys were rather proud of themselves, and as a result, want to try new dishes. Several parents also found that their sons, who had previously never read much a trend that has alarmed educators for several decades had suddenly discovered the joy of books.

More screen time. Online gaming with friends is the main social outlet for boys in isolation, along with other social media, so most parents are allowing more time now than they would have in the past to ensure their sons feel connected with their peers.

Here is the original post:
How not to fight with your teenage son - Sydney Morning Herald

Learning Whats Dangerous Is Costly: Unlocking Fear Response of Social Animals – SciTechDaily

What would you do if the person standing next to you would suddenly scream and run away? Would you be able to carry on calmly with what youre doing, or would you panic? Unless youre James Bond, youre most likely to go for the second option: panic.

But now imagine another scenario: while out on the street, the person walking in front of you suddenly freezes: she stops moving and becomes perfectly still. What would you do?

Here the answer becomes more tricky, says Marta Moita, head of the behavioral Neuroscience lab at the Champalimaud Centre for the Unknown, in Lisbon, Portugal. Even though freezing is one of the three basic instinctive defense behaviors [along with fight and flight], animals dont instinctively know that when others freeze, they are actually responding to a threat.

For social animals such as ourselves, being able to tell if a group member senses a threat, can be a matter of life and death. How does this learning happen? To find an answer to this question, Moita and her team engaged in a series of studies. Their most recent findings are presented in two scientific articles, one that was published today (May 12th) in the journal Plos Biology and another that was published a few months ago in the journalCurrent Biology. Together, their results reveal a mechanism by which animals acquire fear of freezing and outline the neural circuitry that underlies the expression of that fear.

How is it that some fear responses are innate, while others must be learned? The answer is not fully known, but a good guess would be that because the world is ever-changing, animals have to be able to flexibly adapt to their environment.

For instance, when an animal freezes, it essentially stops moving. But is lack of motion necessarily a sign of danger? The answer is no, says Moita. There are situations where an animal stops moving that are perfectly benign; it might be grooming or observing something. But then, this harmless cue can transform into a sign of danger. We wanted to find out how it happens.

In the study published in the journalCurrent Biology, Moita and her team tested various experimental scenarios with rats. They found out that first and foremost, the animal has to go through a process that is called auto-conditioning, meaning that the learning does not happen by observing others, but through first-hand experience. And more than that, it can only happen if specific criteria are fulfilled. We were a bit surprised by the results, because it turns out that the learning mechanism is quite strict, says Andreia Cruz, the first author of the study.

The team discovered that for a rat to adopt freezing as a social cue, it has to go through a learning experience that consists of two key components: pain and immobility. Either one without the other is not enough.

For instance, animals that experience a mild foot shock [which is a painful event] and then freeze as a result, learn to recognize freezing in other group members as a threat. But when we prevented the subsequent freezing response by removing the rat from the experimental box immediately after the foot shock, the learning didnt happen. Cruz explains.

It may seem harsh, but in fact, as Moita points out, this manner of learning is an enormously beneficial way for animals to avoid danger. The rat underwent a single painful experience [a mild foot shock] that taught it that freezing is a response to a negative event. As a consequence, now it doesnt need to learn first-hand the full range of scenarios that can cause painful experiences. Instead, it just needs to be attentive to how its group members behave.

Creating an association between freezing and danger means that new neural connections were formed in the brain. But before diving into the neural circuits, there was still an important question that needed to be addressed: which brain areas might be involved in the expression of this newly learned fear?

Learning happens by associating cognitive elements that were previously unrelated, Moita explains. For instance, in the famous Pavlov experiment, dogs learned that the sound of a bell meant that they were about to receive food. So two previously unrelated things bell sound and food became associated in the brain.

Moita points out that several cognitive elements may be associated with this newly acquired defensive response, among them is a special kind of auditory cue silence.

The team previously discovered that rats who learned to use freezing as an alarm cue were actually detecting the sudden onset of silence. When a rat freezes, it stops moving. Which effectively means that it stops generating sound, Moita explains. We found that this transition from sound to silence can become a social cue by which rats recognize that another group member is freezing.

Following this line of thought, the team focused on the brains fear-learning center and the auditory system. Their results describing a new neural map that spans these structures were published today in the journal Plos Biology.

The first question that comes to mind is: how can the auditory system hear silence? Moita explains that to answer this question, you have to think about it in reverse. We believe that its not silence per se that the brain is detecting, its actually the cessation of sound.

The auditory system is made up of many thousands of neurons, each of which has a personal preference for certain features of auditory information. For example, some neurons respond to high-frequency sounds, others to the onset of sound. And then, there are offset neurons that respond to the cessation of sound. Those are the neurons the team suspects to be the ones that detect silence.

Offset neurons are abundant in a particular area within a brain region called the auditory thalamus. When we blocked the activity of this area, animals that have adapted freezing as a social cue and would normally respond to the sudden onset of silence, did not, explains Ana Perreira, the first author of the study.

Importantly, this same auditory region connects to the lateral amygdala a brain area crucial for learning to respond to threatening sounds. Could it also be involved in fearing silence? The team discovered that the answer is yes. Our results show that the lateral amygdala is not only important for associating sound and danger, but also silence and danger, says Perreira.

The team used these results together with others obtained in this study, to generate a map of how the brain expresses fear of freezing. The pathway we identified expands the network that processes auditory cues in the context of danger, says Moita. More broadly, our work sets the stage to further our understanding of how sensory stimuli and their behavioral relevance are encoded in the brain. she concludes.

Reference: 12 May 2020, Plos Biology.DOI: 10.1371/journal.pbio.3000674

Read this article:
Learning Whats Dangerous Is Costly: Unlocking Fear Response of Social Animals - SciTechDaily

Minnesota Masons give $35 million to the University of Minnesota to establish first-of-its-kind institute devoted to brain development – UMN News

The University of Minnesota has announced a $35 million gift from Minnesota Masonic Charities, an organization that is the Universitys largest single donor. This contribution will establish and name the Masonic Institute for the Developing Brain, an interdisciplinary initiative focused on the early diagnosis, prevention and treatment of neurodevelopmental disorders in early childhood and adolescence.

Led by the Universitys Medical School and College of Education and Human Development (CEHD), this unique institute will bring together teams of researchers and clinicians who study how the brain grows and develops during early childhood and adolescenceformative years when the brain is most receptive to positive intervention. Working together under one roof at the site of the former Shriners Healthcare for Children campus in Minneapolis, an array of experts will tackle such disorders as autism, ADHD, cognitive delays, drug addiction and severe depression, conditions that can often be identified early and have lifelong consequences.

Our long-standing partnership with the University of Minnesota aligns with our mission to make meaningful contributions to society, said Eric Neetenbeek, president and CEO of Minnesota Masonic Charities. The Masonic Institute for the Developing Brain is another example of how we can unite the incredible expertise of the University with the capacity of Minnesota Masonry to benefit our entire state and, indeed, the world.

University of Minnesota President Joan T. A. Gabel, who has made student mental health one of her top priorities, believes the support will improve lives when it matters most. Early support of brain health sets the stage for everything to come in life, she said. Thanks to the Masons transformative gift, the Masonic Institute for the Developing Brain will help ensure that children have the strongest start for a safe, happy and productive life.

In addition to the lead gift from Minnesota Masonic Charities, the University has received generous philanthropic investments in the new institute from the Lynne & Andrew Redleaf Foundation, Otto Bremer Trust, Blythe Brenden-Mann Foundation and Drs. Gail A. Bernstein and Thomas J. Davis Trust.

The institutes mission commits the Universitys world-leading expertise in neuroscience, imaging, child psychology, adolescent psychiatry, developmental disorders and related fields to study precisely how the healthy brain grows and what throws it off course. With this knowledge, doctors and other mental health providers can get young brains back on track before early stressorssuch as malnutrition, trauma and exposure to toxinslead to lifelong complications that can have huge social and economic costs.

During critical periodsparticularly a babys first 1,000 days and adolescencethe brain still has the ability to rewire its connections and make positive, lasting changes, said Dr. Jakub Tolar, dean of the Medical School and vice president for clinical affairs. Early intervention is often a key.

Access is another hurdle facing those who may suffer from symptoms of mental health conditions. Thats a challenge CEHD Dean Jean Quam believes expertise in her college can help address. Our work in interdisciplinary training, telehealth and community outreach will increase access to families and serve as a model for collaboration.

The institutes co-directors, Michael Georgieff and Damien Fair, will lead the institutes cross-disciplinary team of clinicians and researchers. Georgieff, who holds appointments in the Medical School and CEHD, is founding director of the Universitys Center for Neurobehavioral Development. Fair, a national expert in behavioral neuroscience and brain imaging, was recently recruited from Oregon Health & Science University and will join the CEHD and Medical School faculties in July.

Slated to open at its East River Parkway location in fall 2021, the Masonic Institute for the Developing Brain will form a research triangle with M Health Fairview University of Minnesota Masonic Childrens Hospital and the Universitys Biomedical Discovery District. The 10.2-acre property includes a two-level building with a hospital, clinic, and support area, as well as conference space and an attached parking lot.

Minnesota Masonic Charities philanthropic legacy at the U of M:With support from Minnesota Masons, the University built the 80-bed Masonic Memorial Hospital in 1958 and the Masonic Cancer Research Building in the mid-90s. Minnesota Masonic Charities historic $65 million pledge in 2008 to name the Masonic Cancer Center continues to advance major research discoveries. A $10 million gift from the Masons built the Masonic Cancer Clinic, which provides premier cancer care in the M Health Fairview Clinics and Surgery Center on the Twin Cities campus. In addition, a $25 million gift made in 2014 to enhance pediatric research and care brought the Masons total giving to $125 million and led to the renaming of M Health Fairview University of Minnesota Masonic Childrens Hospital. Now, with its latest gift of $35 million to establish and name the Masonic Institute for the Developing Brain, Minnesota Masonic Charities has contributed more than $160 million to the University of Minnesota to accelerate research discoveries in cancer and childrens health that will improve lives throughout Minnesota and beyond. Click hereto view a timeline of giving and the relationship between MMC and the U of M.

View post:
Minnesota Masons give $35 million to the University of Minnesota to establish first-of-its-kind institute devoted to brain development - UMN News

Memory and the brain: the key discovery of Santiago Ramn y Cajal – BBC Focus Magazine

The jelly-like matter of the brain fascinated Spanish pathologist Santiago Ramn y Cajal. In 1877, he saved up all the money he had earned as a medical officer in the Spanish army to buy an old microscope.

For several years he attempted to use the microscope to study and catalogue the tiny structures within the brain, but they were impossible to see clearly.

He wanted to solve the fierce, ongoing debate as to whether the brain was made up of individual cells, or whether these cells were all continuously interconnected.

Santiago Ramn y Cajal Getty Images

In 1873, the Italian physician, Camillo Golgi, developed a staining technique using silver nitrate that allowed a much clearer view of brain tissue. For years, Cajal worked on refining this technique.

As a passionate artist, he drew everything he saw, and in 1889, he presented his findings to the Congress of the German Anatomical Society at the University of Berlin.

Each stained brain cell stood out perfectly. Its complexity could be seen in detail, showing there was no direct physical connection between each cell, and settling the long-running debate.

Cajals intricate brain drawings are still used in neuroscience today Instituto Cajal del Consjo Superior de Investigaciones Cientficas, Madrid/CSIC

Cajals pictures are still used in neuroscience today to demonstrate the precise architecture of the brain that underlies memory, and all other aspects of human thought.

Read more about memory and the brain:

Read this article:
Memory and the brain: the key discovery of Santiago Ramn y Cajal - BBC Focus Magazine

How can diagnostic fertility testing labs help in the battle against COVID-19? – BioNews

11 May 2020

Dr Alan Thornhill, Igenomix UK and School of Biosciences, University of Kent and Professor Darren Griffin, Centre for Interdisciplinary Studies of Reproduction School of Biosciences, University of Kent

As we head into a new phase of theCOVID-19pandemic,there are still many questions unanswered.

FollowingGovernment hints,new guidance from the HFEA, the European Society of Human Reproduction and Embryology and the Association of Reproductive and Clinical ScientistsandBritish Fertility Society,there is understandable relief for fertility professionals and patients that we can gradually begin to restart treatments. Alongside triaging, distancing at work, personal protective equipment (PPE) and other measures as part of a comprehensive risk assessment, there is still a need for testing.

Despite callsfrom the outsetto'test, test, test'from many experts(particularlythe World Health Organisation),we now learn thatthe UK,despite beingone of the world's most advanced and developed nations, has struggled to make it into the'top 40nations',when measuringthe number oftests per million population.

In case it's not entirely clear, there are two types of test:firstly,the antibody test,whichreveals whethera patient hasalreadybeen infected withthe disease and may-though this is not yet certain -be immune. In the absence of a vaccine and safe, effective, accessible therapies, a reliable antibody test will help us to understand the epidemiology of this disease and discover whether we have achieved a level ofpotential'herd immunity'.

Secondly, the PCR, (also known as the diagnostic or antigen)test,uncovers whether you are infected with SARS-CoV-2the virus that causes COVID-19. In both cases, as in most areas of diagnostics, a bad test is worse than no test at all, but this is trueparticularlyfor the PCR test, as false negatives (the testfailing tocorrectlyidentifyinfected people) can lead to infectious individuals further spreading the disease.Combined, these tests could prove a vital'back to work/treatment'strategy for clinic staff and patients alike.

There has been much talk about this so-called immunity passportin the press.It is widelybelieved that,witha combination of accurate, reliable antibody and PCR testing,individuals can be effectively triagedinto work or treatment at low risk, carefully monitored and routinely tested orsent home to self-isolate and recover. Either test alonemay not provide the most comprehensive picture.

As those countries worst affected begin to come out of lockdown and we await a second wave of infection, the PCR testremainskey. PCR is a routine test that allows small amounts of DNAto be replicated in sufficient quantity to analyse. Unfortunately, coronaviruses contain RNA, not DNA, and this is harder to work with, more dangerous and unstable. That's why it is understandable that the UK initially tried torestrictthe testing to Public Health England(PHE)labs,who routinely do this type of work. Surely,therefore, they are the only labs who can do this work properly?

Not necessarily. While no one should dismiss the great work PHE has already done in trying to tackle the coronavirus crisis, there has been a problem from the outset. Right from the beginning, PHE alone never had the required capacity to test all suspected patients, healthcare and care workers; let alone large swathes of the population, in order to isolate infected individuals and reduce disease transmission.

The frustrating thing is that thereis, and alwayshasbeen,a solution.

A UK network of private accredited medical laboratoriesalready exists;manylabsalready offering genetic tests for NHS and private patients. Despite repeated offers to assist,sadly,many have been overlooked. Apart from some notable exceptions like theFrancis Crick Institute, the real success stories outside of PHE are the growing number of laboratories who have joined the COVID-19 testing volunteer network, which, independent of the Government's effort, has steadfastly provided free tests to GPs, care homes and other key workers for many weeks now.

On 2April, Sir Paul Nurse, headof the Crick, indicated that labs like his, not usually involved in viral testing (but nonetheless highly professional andwith sufficient expertisetoperform diagnostictesting) could work alongside the NHS/PHE effort to set up a network of fully functional labs locally. He even evoked the spirit of Dunkirk; small butfunctionaland availableboats ready to assist a mammoth effort inourcountry's hour of need.

Despite this inspirationaland very public'call to arms', many offers to help have gone unheard.Indeed, ourISO 15189-accredited laboratory(normally providing genetic tests toclinicstohelp fertility patientshave a better chanceof havinghealthy children) registered earlywith the various Government agencies involved in tackling theCOVID-19crisis,offeringbothequipment and staff. From day one, we have always been willing to help with testingand believed that a risk-managed approach to mass testing should always include a network of high quality (ideally accredited) laboratories to provide local testingincase ofthecatastrophic failure at a so-called 'megalab'.

Without officialrecognition orsupport, however,we have faced significant challenges of reagent and equipment shortage or national requisitioning and have had to'go it alone'.At many stages we have even reached out to IVF clinics to source equipment and have been genuinely moved bytheirwillingness towork together to solve problems the Dunkirk spirit in action!

We are now in astrongposition toprovide PCR (and antibody) testing to clinics and their patientsand tohelp the wider community,aswe gradually come out of lockdown and are braced for second and subsequent waves of infection.We further hope thatthis huge effort, investment and risk is worth it in the longer term,as we try to better understand the impact ofviral infection generally (and SARS-CoV-2 specifically) on fertility and pregnancy,as this is still not well understood.

As we all try to find our 'new normal', we need to continue to be flexible, dynamic and supportive in our collective efforts to help patients. Despite the Government's assurance that we now have national capacity of 100,000 PCR tests per day with a new 'target' set of 200,000 tests per day by the end of May, we urge fertility clinic staff especially to ensure that they truly have free and easy access to these tests especially if asymptomatic.

Many may have heard about the key worker testing website crashing on day one, the long queues at drive-through test centres only to have a self-administered swab kit launched through the hastily opened car window, testing kits being sent out with no return address and there are, no doubt, many other such troubling stories.

What the Government and PHE have finally achieved is incredible, but the new challenge may not be testing capacity intrinsically, but easy access to high-quality tests, timely reporting and focused customer support for asymptomatic individuals. This is where smaller, private laboratories may show their true worth. It's time we considered them. To use the Dunkirk metaphor - let's launch those boats! With daily declining fatality rates and the peak of infections behind us, the battle may be over for now. But the war is certainly not yet won.

Continue reading here:
How can diagnostic fertility testing labs help in the battle against COVID-19? - BioNews

MSc virologists explore infections and cell biology in new virtual laboratory | Imperial News – Imperial College London

As part of the College's move to remote learning, XX MSc Molecular Biology & Virology students are trialling remote research in a 'virtual lab'.

Students and staff in the Department of Infectious Disease are exploring the new format of teaching and learning over the course of the summer, while laboratory access continues to be limited.

The 'virtual, remote research projects' will now take the place of the remaining five months of the 'Laboratory Based Research Project', the final module on the programme.

From the outset the Department wanted to create an experience, at pace, that contrasted to the less interactive learning experience offered by a literature review.

Reflecting on the shift to virtual labs, Martin Lupton,Vice-Dean (Education) in the Faculty of Medicine, said:"Now more than ever the world needs experts in the medical field to tackle current and future global challenges. This means that lab work cannot simply 'pause', but needs to continue in a format that works well for our students.

"We are making plans to deliver programmes in a number of ways, dependent on progress in the fight against COVID-19. Through our campuses and our remote and online offerings we look forward to providing current and new students freshperspective in their chosendisciplines."

Delivering engaging and impactful research projects without easy access to a laboratory is a challenge, but oneembraced by the Department. Students' projects would always have taken place through conversation and supervision, including technical training, application of techniques in the lab, proper construction and design of experiments, and students' interpretation and presentation of data.

This practical experience of learning in a physical lab setting is a 'gold standard', according Mr Lupton and colleagues. Yet, it is possible in a virtual lab to create an environment where students gain the skills needed for working in a real lab.

XXX XXXX, an MSc student who is taking part in the virtual lab, said: ""

After being provided with direct, online training from research group leaders, and setting their key objectives, students are expected to:

Chair in Virology, and the originator of the idea of a 'virtual lab' for the programme, Professor Peter O'Hare, said: "Until we have a clearer sense of when and how it may be possible to return to on-campus labs, it's important that our students can tackle a range of research projects even if we must continue to be creative with a remote format.

"By offering a 'virtual lab' the team hope to equip students withpractical techniques and skills in data handling, interpretation, and critical evaluation. Bringing this all together as Remote Research Reports will prove to be an unexpected but hopefully interesting challenge.

"Just like any normal lab meeting or interaction, support and guidance will be on-hand for all students."

Complementary to this supportive environment research group leaders do also want to emphasise the benefits of independent learning, and participants having confidence in their own abilities. Students will still be expected to investigate research techniques independently and work closely with staff to recognise when they should move onto their next assignment.

All postgraduate programmes in the Faculty of Medicine are available to browse online. Application and enrolment dates remain unchanged by the COVID-19 outbreak.

The College's Graduate School is at the centre of the postgraduate community and provides details on what studying at Imperial is like.

Current and prospective students can view a wide selection of answers to frequently asked questions on the College's regularly updated COVID-19 webpages.

See more here:
MSc virologists explore infections and cell biology in new virtual laboratory | Imperial News - Imperial College London